Your browser is no longer supported. Please, upgrade your browser.
Settings
NVLN Novelion Therapeutics Inc. daily Stock Chart
NVLN [NASD]
Novelion Therapeutics Inc.
Index- P/E- EPS (ttm)-5.68 Insider Own0.10% Shs Outstand18.85M Perf Week-4.49%
Market Cap16.02M Forward P/E- EPS next Y-3.33 Insider Trans-95.98% Shs Float16.73M Perf Month-28.57%
Income-107.30M PEG- EPS next Q-0.18 Inst Own45.80% Short Float0.72% Perf Quarter-29.17%
Sales135.10M P/S0.12 EPS this Y15.40% Inst Trans-5.61% Short Ratio0.93 Perf Half Y-19.81%
Book/sh-6.25 P/B- EPS next Y25.80% ROA-31.80% Target Price6.50 Perf Year-78.75%
Cash/sh2.75 P/C0.31 EPS next 5Y- ROE133.40% 52W Range0.70 - 4.10 Perf YTD1.19%
Dividend- P/FCF- EPS past 5Y-17.80% ROI-21.60% 52W High-79.27% Beta2.28
Dividend %- Quick Ratio0.20 Sales past 5Y- Gross Margin54.60% 52W Low21.43% ATR0.07
Employees109 Current Ratio0.20 Sales Q/Q17.10% Oper. Margin-36.20% RSI (14)37.92 Volatility4.85% 11.25%
OptionableYes Debt/Eq- EPS Q/Q4.60% Profit Margin-79.40% Rel Volume0.46 Prev Close0.86
ShortableYes LT Debt/Eq- EarningsMar 21 BMO Payout- Avg Volume129.99K Price0.85
Recom3.00 SMA20-2.24% SMA50-25.06% SMA200-39.69% Volume59,316 Change-1.16%
Feb-07-17Reiterated RBC Capital Mkts Sector Perform $13.50 → $10
Jun-19-19 06:25AM  Can We See Significant Institutional Ownership On The Novelion Therapeutics Inc. (NASDAQ:NVLN) Share Register? Simply Wall St.
May-21-19 02:35AM  UK's Amryt Pharma unites lomitapide franchise with Aegerion deal Reuters -26.65%
May-20-19 10:53PM  Novelion Therapeutics Announces Subsidiary Aegerion Pharmaceuticals to Recapitalize Through Court Supervised Process In Which Amryt Pharma Plc Will Acquire 100% of Reorganized Stock of Aegerion GlobeNewswire
May-07-19 05:19PM  Novelion Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Novelion Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire
Mar-31-19 02:00AM  Novelion Therapeutics Observes World Lipodystrophy Day GlobeNewswire
Mar-15-19 09:48PM  Novelion Therapeutics Inc (NVLN) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Mar-14-19 06:57PM  Novelion Therapeutics: 4Q Earnings Snapshot Associated Press
05:12PM  Novelion Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Feb-28-19 07:00AM  Novelion Therapeutics Observes Rare Disease Day GlobeNewswire -9.60%
Feb-07-19 09:00AM  Biotech Stocks Set to Pop ACCESSWIRE
Feb-06-19 02:30AM  Novelion Therapeutics Subsidiary Enters Into Licensing Agreement for JUXTAPID® in Japan GlobeNewswire +31.33%
Dec-28-18 07:06AM  5 Top Rising P/E Stocks to Enjoy Solid Gains Zacks
Dec-05-18 06:50AM  Today's Research Reports on Trending Tickers: Novelion Therapeutics and Revance Therapeutics ACCESSWIRE
Dec-04-18 10:33AM  Novelion Rises 50% After Activist Investor Demands Exploration Of Strategic Alternatives Benzinga +32.65%
Nov-27-18 06:50AM  Today's Research Reports on Trending Tickers: Novelion Therapeutics and ReShape Lifesciences ACCESSWIRE -7.08%
Nov-21-18 09:25AM  New Healthcare Trends Could Push Sector Stocks Higher ACCESSWIRE +8.73%
08:04AM  The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO Benzinga
Nov-20-18 04:05PM  Novelion Therapeutics Announces Leadership Change GlobeNewswire -9.95%
Nov-09-18 08:46AM  Novelion Therapeutics Reports Third Quarter 2018 Financial Results GlobeNewswire +36.80%
06:55AM  Todays Research Reports on Stocks to Watch: Perrigo Company and Novelion Therapeutics ACCESSWIRE
Nov-08-18 08:48AM  Novelion Therapeutics Subsidiary Enters Into Term Loan Agreement and Novelion Provides Business Update GlobeNewswire +77.23%
Sep-24-18 08:30AM  Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day GlobeNewswire -6.50%
Aug-23-18 07:43AM  Novelion Therapeutics Announces Next Phase of Operational Improvements GlobeNewswire
Aug-07-18 08:43AM  Novelion Therapeutics: 2Q Earnings Snapshot Associated Press
08:30AM  Novelion Therapeutics Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-31-18 08:15AM  Novelion Therapeutics Announces Marketing Authorization for MYALEPTA® (metreleptin) in the European Union to Treat Generalized and Partial Lipodystrophy GlobeNewswire +5.46%
Jul-03-18 08:30AM  Novelion Therapeutics Appoints Mark Corrigan, M.D. as Executive Chair of the Board of Directors GlobeNewswire -5.78%
Jun-25-18 08:01AM  Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions GlobeNewswire
08:00AM  Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions GlobeNewswire
Jun-08-18 03:40PM  Should You Invest In The Healthcare Sector And Novelion Therapeutics Inc (NASDAQ:NVLN)? Simply Wall St.
Jun-01-18 08:13AM  MYALEPTA® (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy GlobeNewswire -7.38%
07:54AM  MYALEPTA® (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy GlobeNewswire
May-22-18 10:03AM  Analysts Expect Breakeven For Novelion Therapeutics Inc (NASDAQ:NVLN) Simply Wall St. -5.12%
May-15-18 05:59PM  Former Aegerion sales rep charged with defrauding U.S. insurers Reuters
May-10-18 08:47AM  Novelion Therapeutics: 1Q Earnings Snapshot Associated Press -6.10%
08:30AM  Novelion Therapeutics Reports First Quarter 2018 Financial Results GlobeNewswire
Apr-18-18 05:57PM  Novelion Therapeutics Inc (NASDAQ:NVLN): What Can We Expect From This High Growth Stock? Simply Wall St.
Apr-02-18 09:27PM  Does Novelion Therapeutics Incs (NASDAQ:NVLN) -139.66% Earnings Drop Reflect A Longer Term Trend? Simply Wall St.
Mar-31-18 06:01AM  Novelion Therapeutics Supports World Lipodystrophy Day GlobeNewswire
06:00AM  Novelion Therapeutics Supports World Lipodystrophy Day GlobeNewswire
Mar-15-18 07:33PM  Novelion Therapeutics reports 4Q loss Associated Press -7.38%
05:17PM  Novelion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
05:10PM  Novelion Therapeutics Subsidiary Enters into $20 Million Term Loan Agreement with Sarissa Capital and Broadfin Capital GlobeNewswire
Mar-01-18 10:30AM  Doctor pleads guilty as part of Aegerion drug misbranding probe American City Business Journals
Feb-28-18 03:04PM  Doctor admits disclosing patient info to drugmaker Aegerion Reuters -7.80%
07:01AM  Novelion Therapeutics Observes Rare Disease Day GlobeNewswire
07:00AM  Novelion Therapeutics Observes Rare Disease Day GlobeNewswire
Jan-30-18 05:51PM  Novelion Therapeutics Announces Sentencing of Subsidiary Aegerion Pharmaceuticals GlobeNewswire +8.08%
04:49PM  U.S. judge sentences Novelion's Aegerion in drug marketing case Reuters
07:00AM  Novelion's Aegerion faces sentencing in U.S. drug marketing case Reuters
Jan-24-18 04:01PM  Novelion Therapeutics Announces Cost Reduction Plans and Capital Structure Review GlobeNewswire
Jan-10-18 03:32PM  How Should You Think About Novelion Therapeutics Incs (NASDAQ:NVLN) Risks? Simply Wall St.
Dec-22-17 12:45PM  Aegerion says judges rejection of $40M plea clouds future American City Business Journals -5.49%
11:09AM  Novelion unit asks U.S. judge to approve plea deal, cites money woes Reuters
Dec-15-17 04:15PM  Is Novelion Therapeutics Inc (NASDAQ:NVLN) Cheap And High Growth? Simply Wall St.
Dec-04-17 08:30AM  Novelion Therapeutics Appoints Michael Price as Senior Vice President and Chief Financial Officer GlobeNewswire
Nov-27-17 11:50AM  What Investors Should Know About Novelion Therapeutics Incs (NVLN) Financial Strength Simply Wall St. +5.31%
Nov-21-17 08:30AM  Novelion Therapeutics Provides Update on Agreement between Aegerion Pharmaceuticals and U.S. Department of Justice GlobeNewswire -9.60%
Nov-10-17 05:35PM  Should You Buy Novelion Therapeutics Inc (NVLN)? Simply Wall St.
Nov-09-17 08:45AM  Novelion Therapeutics reports 3Q loss Associated Press
08:28AM  Novelion Therapeutics Reports Third Quarter 2017 Financial Results and Announces Leadership Change GlobeNewswire
Nov-01-17 04:54PM  U.S. submits revised plea deal with Novelion's Aegerion to court Reuters
Oct-31-17 08:30AM  Novelion Therapeutics Expands Leadership Team with Appointment of Jeffrey Hackman as Chief Operating Officer GlobeNewswire
Oct-18-17 04:49PM  U.S. judge says he may reject plea deal with Novelion's Aegerion Reuters
Oct-12-17 09:15AM  Novelion Therapeutics Strengthens Leadership Team with Appointment of Murray Stewart, M.D., as Executive Vice President, Head of R&D GlobeNewswire
Sep-26-17 07:30AM  Corporate News Blog - Novelion's Subsidiary Aegerion Pleads Guilty for Misbranding Juxtapid; Agrees to a Settlement of $40 Million ACCESSWIRE
Sep-25-17 04:17PM  Patient assistance charity says U.S. contacted it in probe Reuters
Sep-24-17 08:00AM  Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day GlobeNewswire
Sep-22-17 08:52PM  Novelion's Aegerion resolves U.S. drug probes for $40 mln Reuters
04:50PM  Aegerion finalizes $40M settlement, guilty plea in drug misbranding case American City Business Journals
03:36PM  Novelion's Aegerion resolves U.S. drug probes for $40 mln Reuters
01:20PM  SEC fines pharmaceutical company $4.1 million for misleading performance metric MarketWatch
Sep-15-17 08:30AM  Metreleptin and Lipodystrophy Data Presented at the International Meeting of Pediatric Endocrinology GlobeNewswire
Sep-11-17 08:30AM  Novelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of Directors GlobeNewswire
Aug-08-17 09:32PM  Novelion Therapeutics reports 2Q loss Associated Press -12.26%
07:00AM  Novelion Therapeutics Reports Second Quarter 2017 Financial Results GlobeNewswire
Aug-02-17 08:30AM  Novelion Therapeutics Appoints Mark DiPaolo to Board of Directors GlobeNewswire
Jul-28-17 08:30AM  Novelion Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017 GlobeNewswire
Jun-26-17 08:30AM  Novelion Therapeutics Added to the Russell 3000® & Russell Microcap® Indexes GlobeNewswire -5.96%
Jun-12-17 08:30AM  Novelion Therapeutics Announces Presentation of Metreleptin Data at American Diabetes Association GlobeNewswire
Jun-01-17 04:01PM  Novelion Therapeutics Appoints John J. Orloff, M.D., to Its Board of Directors, Steps Down as EVP, Head of R&D GlobeNewswire
May-09-17 07:00AM  Novelion Therapeutics Reports First Quarter 2017 Financial Results GlobeNewswire
07:00AM  Investor Network: Novelion Therapeutics Inc. to Host Earnings Call Accesswire
May-05-17 09:00AM  Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology GlobeNewswire
May-03-17 04:15PM  Novelion Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017 GlobeNewswire
Apr-25-17 09:15AM  Novelion Therapeutics Announces Presentation at the Bloom Burton & Co. Healthcare Investor Conference GlobeNewswire
Apr-19-17 04:15PM  Novelion Therapeutics Request to Voluntarily Delist from the Toronto Stock Exchange Granted GlobeNewswire
Apr-04-17 04:10PM  Metreleptin and Lipodystrophy Data Presented at the Annual Meeting of the Endocrine Society GlobeNewswire
04:10PM  Metreleptin and Lipodystrophy Data Presented at the Annual Meeting of the Endocrine Society
Mar-31-17 08:30AM  NOVELION THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
08:00AM  Novelion Therapeutics Appoints Mark Corrigan, M.D. to Board of Directors GlobeNewswire
06:00AM  Novelion Therapeutics Observes World Lipodystrophy Day GlobeNewswire
Mar-30-17 04:17PM  NOVELION THERAPEUTICS INC. Files SEC form 10-K, Annual Report
04:15PM  Novelion Therapeutics Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine Society GlobeNewswire
Mar-15-17 07:28AM  Novelion Therapeutics reports 4Q loss Associated Press
07:28AM  Novelion Therapeutics reports 4Q loss
07:15AM  NOVELION THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or
07:00AM  Novelion Therapeutics Reports Preliminary Fourth Quarter & Full Year 2016 Financial Results GlobeNewswire
Mar-13-17 04:15PM  Novelion Therapeutics to Announce Preliminary Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017 GlobeNewswire
Novelion Therapeutics Inc., a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPTA brand name; and lomitapide capsule for the treatment of adult patients with homozygous familial hypercholesterolemia under the JUXTAPID and LOJUXTA brands. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Broadfin Healthcare Master Fun10% OwnerDec 27Sale0.86171,116146,3071,498,553Dec 27 05:34 PM
Broadfin Healthcare Master Fun10% OwnerDec 26Sale0.91278,485254,7151,669,669Dec 27 05:34 PM
Broadfin Healthcare Master Fun10% OwnerDec 24Sale0.984003921,948,154Dec 27 05:34 PM